当前位置: X-MOL 学术Helv. Chimica Acta › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Synthesis, in silico and in vitro Evaluation of Novel Oxazolopyrimidines as Promising Anticancer Agents
Helvetica Chimica Acta ( IF 1.8 ) Pub Date : 2020-10-09 , DOI: 10.1002/hlca.202000169
Yevheniia Velihina 1, 2 , Thomas Scattolin 3 , Denys Bondar 1 , Stepan Pil'o 2 , Nataliya Obernikhina 4 , Olesksiy Kachkovskyi 2 , Ivan Semenyuta 2 , Isabella Caligiuri 5 , Flavio Rizzolio 5, 6 , Volodymyr Brovarets 2 , Yevgen Karpichev 1 , Steven P. Nolan 3
Affiliation  

New potential bioactive oxazolopyrimidines have been synthesized using two main approaches: the pyrimidine ring annulation on a functionalized oxazole and the benzoyl bromide trimerization followed by rearrangement and formation of the oxazolo[5,4‐d]pyrimidine scaffold. The docking analyzes have shown that 7‐piperazine substituted oxazolo[4,5‐d]pyrimidines 8a8c could be potential VEGFR2 inhibitors with high free energy of ligand–protein complex formation (ΔG: −10.1, −9.6, −9.8 kcal/mol, respectively). In vitro antitumor assays confirmed theoretical predictions that oxazolo[4,5‐d]pyrimidines 8a8c containing positively charged piperazine moiety should demonstrate significantly higher cytotoxic effects. 4‐[5‐(4‐Chlorophenyl)‐2‐phenyl[1,3]oxazolo[4,5‐d]pyrimidin‐7‐yl]piperazin‐1‐ium trifluoroacetate (8c) exhibited a slightly higher antiproliferative effect (IC50=0.21 μm) than doxorubicin (IC50=0.36 μm) on MDA‐MB‐231 cell line and has relatively good results on OVCAR‐3 (IC50=1.7 μm) and HCT‐116 (IC50=0.24 μm) cells.

中文翻译:

新型恶唑嘧啶类化合物的合成,计算机模拟和体外评价,新型恶唑嘧啶类化合物的合成,计算机模拟和体外评价

使用两种主要方法合成了新的潜在生物活性恶唑并嘧啶:在功能化的恶唑上环嘧啶环和苯甲酰溴三聚,然后重排和形成恶唑并[5,4- d ]嘧啶骨架。对接分析表明,7-哌嗪取代的恶唑并[4,5- d ]嘧啶8a - 8c可能是潜在的VEGFR2抑制剂,具有高自由能的配体-蛋白质复合物形成(ΔG:-10.1,-9.6,-9.8 kcal / mol)。体外抗肿瘤试验证实了恶唑并[4,5- d ]嘧啶8a - 8c的理论预测含有带正电荷的哌嗪部分的化合物应显示出明显更高的细胞毒性作用。4- [5-(4-氯苯基)-2-苯基[1,3]恶唑[4,5 - d ]嘧啶-7-基]哌嗪-1-三氟乙酸铵(8c)表现出较高的抗增殖作用(IC 50 = 0.21μ)比多柔比星(IC 50 = 0.36μ对MDA-MB-231细胞系),并且对OVCAR-3(比较好的效果IC 50 = 1.7μ)和HCT-116(IC 50 = 0.24 μ)细胞。,使用两种主要方法合成了新的潜在生物活性恶唑并嘧啶:在功能化的恶唑上环嘧啶环和苯甲酰溴三聚,然后重排和形成恶唑并[5,4- d ]嘧啶骨架。对接分析表明,7-哌嗪取代的恶唑并[4,5- d ]嘧啶8a - 8c可能是潜在的VEGFR2抑制剂,具有高自由能的配体-蛋白质复合物形成(ΔG:-10.1,-9.6,-9.8 kcal / mol)。体外抗肿瘤试验证实了恶唑并[4,5- d ]嘧啶8a - 8c的理论预测含有带正电荷的哌嗪部分的化合物应显示出明显更高的细胞毒性作用。4- [5-(4-氯苯基)-2-苯基[1,3]恶唑[4,5 - d ]嘧啶-7-基]哌嗪-1-三氟乙酸铵(8c)表现出较高的抗增殖作用(IC 50 = 0.21μ)比多柔比星(IC 50 = 0.36μ对MDA-MB-231细胞系),并且对OVCAR-3(比较好的效果IC 50 = 1.7μ)和HCT-116(IC 50 = 0.24 μ)细胞。
更新日期:2020-12-11
down
wechat
bug